Lizzul Paul F., CMO, reported a transaction classified as grant at First Tracks Biotherapeutics, Inc. involving 60492.000000 shares for an estimated $0.00. Reported holdings after the transaction were 137651.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
Form 4 relationship flags and nearby filing context
Chief Medical Officer
Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of…
Each PSU represents a conditional right to receive one share of the Issuer's Common Stock.
The PSUs vest and settle over two years; 50% vests on August 15, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date.
0 other filings
0 recent txs